/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

ALX ONCOLOGY HOLDINGS INC Share Price Today: Live Updates & Key Insights

ALX ONCOLOGY HOLDINGS INC share price today is $2.02, up -6.05%. The stock opened at $2.08 against the previous close of $2.15, with an intraday high of $2.1 and low of $1.99.

ALX ONCOLOGY HOLDINGS INC Share Price Chart

style
pb-0

ALX ONCOLOGY HOLDINGS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

ALX ONCOLOGY HOLDINGS INC Share Price Performance

$2.02 -0.0605(-6.05%) ALXO at 13 Mar 2026 11:58 AM Biotechnology
Lowest Today 1.99
Highest Today 2.1
Today’s Open 2.08
Prev. Close 2.15
52 Week High 2.66
52 Week Low 0.40
Day’s Range: Low 1.99 High 2.1
52-Week Range: Low 0.40 High 2.66
1 day return -
1 Week return -8.37
1 month return -8.78
3 month return +43.1
6 month return +92.85
1 year return +141.76
3 year return -64.15
5 year return -97.35
10 year return -

ALX ONCOLOGY HOLDINGS INC Institutional Holdings

venBio Partners LLC 7.39

HBM Healthcare Investments AG Ord 3.64

Redmile Group, LLC 2.54

Millennium Management LLC 2.00

Almitas Capital LLC 1.93

Vanguard Group Inc 1.24

Driehaus Capital Management LLC 1.08

Acadian Asset Management LLC 0.93

Vanguard Total Stock Mkt Idx Inv 0.73

Two Sigma Advisers, LLC 0.54

Ameriprise Financial Inc 0.50

Two Sigma Investments LLC 0.49

Bank of America Corp 0.40

Bank of Montreal 0.36

BMO Capital Markets Corp. 0.36

BlackRock Inc 0.34

Renaissance Technologies Corp 0.32

Geode Capital Management, LLC 0.27

Vanguard Institutional Extnd Mkt Idx Tr 0.27

Fidelity Extended Market Index 0.14

Jane Street Group LLC 0.14

UBS Group AG 0.13

JPMorgan Chase & Co 0.09

Susquehanna International Group, LLP 0.09

Vanguard Health Care ETF 0.06

Blackrock Extended Mkt Fund CF 0.05

Bridgeway Ultra-Small Company Market 0.05

Extended Equity Market Fund K 0.04

Fidelity Total Market Index 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Fidelity Series Total Market Index 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Spartan Extended Market Index Pool F 0.03

Vanguard Balanced Index Inv 0.03

Northern Trust Extended Eq Market Idx 0.02

Spartan Total Market Index Pool G 0.02

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

Northern Small Cap Core I 0.01

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

ALX ONCOLOGY HOLDINGS INC Market Status

Strong Buy: 3

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

ALX ONCOLOGY HOLDINGS INC Fundamentals

Market Cap 282.44 M

PB Ratio 6.4134

PE Ratio 0.0

Enterprise Value 231.56 M

Total Assets 59.05 M

Volume 295677

ALX ONCOLOGY HOLDINGS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:1182000 1.2M, FY19:4796000 4.8M

Annual Profit FY23:null 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:107000 0.1M, FY19:436000 0.4M

Annual Net worth FY23:-146042000 -146.0M, FY22:-123482000 -123.5M, FY21:-83463000 -83.5M, FY20:-45740000 -45.7M, FY19:-19243000 -19.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-191000 -0.2M, Q1/2025:-211000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-220000 -0.2M

Quarterly Net worth Q3/2025:-22144000 -22.1M, Q2/2025:-25949000 -25.9M, Q1/2025:-30754000 -30.8M, Q3/2024:-30707000 -30.7M, Q2/2024:-39399000 -39.4M

About ALX ONCOLOGY HOLDINGS INC & investment objective

Company Information ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 44

Industry Biotechnology

CEO Mr. Jason W. Lettmann

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow